We are live on ! Find out more
AEON icon

AEON Biopharma

16 hedge funds and large institutions have $885K invested in AEON Biopharma in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more capital inflows, than outflows

Capital inflows: $10.5M | Capital outflows: $2.86M

7.72% less ownership

Funds ownership: 22.22% → 14.5% (-7.7%)

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

57% less funds holding

Funds holding: 37 → 16 (-21)

88% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 24

Holders
16
Holders Change
-21
Holders Change %
-56.76%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
6
Closed
24
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

AEON Hedge Fund Activity: Q1 2025 in Review

16 of the 7,493 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q1 2025, worth a combined $885K — down 82% from $4.8M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of AEON and 3 opened new positions — a net loss of 21 holders — while 6 trimmed existing stakes and 4 added.

The largest buyer was Dauntless Investment Group, opening a new position worth an estimated $7.3M. The largest seller was Polar Asset Management Partners, exiting entirely with an estimated $1.49M sold.

  • 16 institutional investors held AEON Biopharma (AEON) as of Q1 2025, down from 37 in Q4 2024.
  • Funds reported $885K of AEON Biopharma stock for Q1 2025, down 82% quarter-over-quarter.
  • 3 funds opened new AEON Biopharma positions in Q1 2025 and 24 closed out, a net change of -21 holders.
  • The largest AEON Biopharma buyer in Q1 2025 was Dauntless Investment Group, an estimated $7.3M added.
  • The largest AEON Biopharma seller in Q1 2025 was Polar Asset Management Partners, an estimated $1.49M sold.

Based on aggregated 13F filings for Q1 2025.